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Abstract
Background: Nitric oxide (NO) is known to be a signaling
molecule with many physiogical functions including apop-
totic process regulation. Since apoptosis may contribute to
the pathophysiology of schizophrenia, this study was under-
taken to determine the plasma concentrations of NO in
schizophrenics.
Methods: Nitrite/nitrate (NO2–/NO3–) concentrations were
measured in plasma from 40 patients with schizophrenia, and
36 age- and gender-matched healthy persons using a colori-
metric test.
Results: Plasma NO2–/NO3– concentrations were signifi-
cantly higher in patients with schizophrenia (102.8"34.7
mmol/L, p-0.0001) than in controls (69.2"13.2 mmol/L).
Also, mean NO2–/NO3– values in female patients and con-
trols were significantly higher (118.2"44.7 mmol/L,
p-0.001; 74.8"16.1 mmol/L, p-0.05, respectively) com-
pared to males (94.7"25.3 mmol/L, 67.6"10.8 mmol/L).
Significant correlation was seen between plasma NO2–/NO3–
concentrations and heredity, number of episodes and periph-
eral blood mononuclear cell (PBMC) caspase-3 activity,
which was significantly higher in patients than in controls
(p-0.05). There was no significant difference in NO2–/NO3–
concentrations between patients with different Positive and
Negative Syndrome Scale (PANSS) scores or between
patients treated with haloperidol (97.2"31.2 mmol/L) and
those treated with other atypical antipsychotic drugs
(109.8"33.7 mmol/L). Both parameters showed no signifi-
cant differences between smokers and non-smokers.
Conclusions: This study showed that plasma NO2–/NO3–
concentrations were significantly increased in patients with
schizophrenia, being significantly higher in female than male
patients, and showing a significant correlation with heredity,
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number of episodes and PBMC caspase-3 activity. These
results suggest that NO could be considered an inducer or
regulator of apoptosis in patients with schizophrenia.
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Introduction
Although initially described as a mediator of endo-
thelial relaxation, nitric oxide (NO) is recognized in numer-
ous physiological processes including vasodilation, neuro-
transmission, immune and apoptosis regulation, and killing
of intracellular pathogens. In the nervous system, NO is
involved in corticotropin-releasing factor release, cytokine-
mediated release of adrenocorticotropic hormone, cyclooxy-
genase and guanylate cyclase activation, and oxytocin and
vasopressin secretion (1). NO is produced from the semi-
essential amino acid L-arginine by two constitutive isoforms
of nitric oxide synthase (NOS), endothelial NOS (eNOS,
NOS3) and neuronal NOS (nNOS, NOS1). L-arginine is both
the substrate and the regulator of NOS (2). The third isoform
(iNOS, NOS2) is induced in inflammatory, endothelial, mus-
cle and other cells by a wide range of inflammatory agents,
especially cytokines (3), and bacterial endotoxines. eNOS
can also be induced in some settings (4). However, unregu-
lated NO synthesis, associated with either higher or lower
NO availability, may have deleterious effects. Increased NO
production may lead to nitrosylation of biomolecules and to
reaction with superoxide, forming a very toxic peroxynitrite
anion (5) capable of reacting with various biomolecules.
Decreased NO may disturb physiological NO effects.
These toxic effects are involved in many human
diseases including atherosclerosis, immune-mediated inflam-
matory processes, and ischemic cell death (6). NO is also
suggested as a cytotoxic factor which induces apoptosis in
neurodegenerative diseases as well as schizophrenia (7).
Recently, it was shown that animals treated with a substance
that blocks brain NO production became resistant to the
schizophrenia-like effects of phencyclidine (8). In another
study, the authors noted that plasma arginase activity and Mn
were significantly decreased and total nitrite level was
increased in patients with schizophrenia compared to controls
(9). These findings suggest that a disturbed arginine-NO
pathway may increase cell susceptibility to apoptosis, and
may therefore be involved in the pathogenesis of schizo-
phrenia. To test this hypothesis, we measured plasma nitrite/
nitrate (NO2–/NO3–) concentrations and peripheral blood
mononuclear cell (PBMC) caspase-3 activity in patients with
schizophrenia and correlated these parameters with patient
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Table 1 Demographic, clinical and pharmacotherapeutic characteristics of patients with schizophrenia.
Schizophrenia Control
Male/female, n 24/16 22/14
Age, years 30.2"7.9 29.8"5.8
Heredity (q/–) 16/24 –
Age of disease manifestation, years Between 18 and 34 –
Duration of psychiatric disease, years 1–)5 –
Number of episodes 1–7 –
PANSS positive scores predominant ()3) 20 –
PANSS negative scores predominant (-–8) 12 –
PANSS positive and negative scores almost equally expressed ()–8-3) 8 –
Haloperidol treated, n 18 –
Atypical antipsychotic drugs treated, n 22 –
Smokers, % 59 43
Non-smokers, % 41 57
clinical characteristics, Positive and Negative Syndrome
Scale (PANSS) scores and drug treatment.
Patients and methods
Patients were recruited at the Clinic of Psychiatry and the Clinic
for Mental Health Protection of the Clinical Centre Nisˇ. Subjects
were assessed with the Diagnostic Interview for Psychosis by two
independent psychiatrists, and diagnosed according to DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders, 4th ed) and
ICD-10 (International Statistical Classification of Diseases and
Related Health Problems, 10th revision). For disease evaluation and
clinical management of patients, the PANSS was used for scoring
positive symptoms (hallucinations, delusions of grandeur, disor-
dered thought processes and bizarre behaviors), negative symptoms
(social withdrawal, flat affect, loss of pleasurable feelings, reduced
motivation, reduced speech output and cognitive disturbances) and
general psychopathology scale which presented the structure of clin-
ical disease manifestation. Each patient was tested and classified
into one of three groups according to the score values: a group with
PANSS positive score predominance (the values of score higher than
3), a group with PANSS negative score predominance (score values
lower than –8), and a group showing positive and negative symp-
toms almost equally (score values near 0). Patients with immune,
inflammatory and liver diseases were excluded from the study.
The study included 40 schizophrenic patients (24 males, 16
females; mean age 30.2"7.9) and 36 healthy controls (22 males,
14 females; mean age 29.8"5.8) recruited at the Department for
Blood Transfusion. The patients and controls were matched accord-
ing to age, gender, marital status, education, living conditions, living
settings and habits.
All subjects provided written informed consent and the study was
approved by the Clinical Center Nisˇ Ethics Committee.
Venous blood was collected in vacutainer tubes containing potas-
sium EDTA as anticoagulant. Plasma samples were stored at –208C
until measurement of NO2–/NO3–. Concentrations of NO2–/NO3–
were measured using the modified cadmium-reduction method of
Navaro-Gonzalvez et al. (10) based on the Griss reaction. PBMCs
were isolated from peripheral blood using lymphocyte separation
medium (PAA, Pashing, Austria). Caspase-3 activity was measured
using a colorimetric commercially available ELISA kit (Bio Source
Europe S.A, Novellas, Belgium), and expressed per mg of protein.
Data analysis was performed using the SigmaStat computer pro-
gram. Differences between groups were assessed using the Mann-
Whitney rank sum test (ANOVA). Correlations between NO2–/NO3–
concentrations and demographic, clinical and therapeutic character-
istics of patients were assessed using Pearson’s coefficient.
Results
The demographic characteristics of patients with schizophre-
nia and healthy controls are shown in Table 1. Patients and
healthy subjects were matched for age and gender. Heredity
was present in 16 of 40 schizophrenics. Age of disease man-
ifestation was between 18 and 34 years. The duration of
psychiatric disease was from 1 to )5 years. The patients
had 1–7 episodes before inclusion in the study. In 20
patients, positive symptoms were predominant, in 12 nega-
tive symptoms predominated, and in eight both types of
symptoms were almost equally expressed. Eighteen patients
were treated with haloperidol and 22 with atypical antipsy-
chotic drugs; 24 patients were smokers and 16 were non-
smokers. The control group included 15 smokers and 21
non-smokers.
Plasma NO2–/NO3– concentrations in patients with schizo-
phrenia were significantly increased (102.8"34.7 mmol/L,
p-0.001) when compared with controls (69.2"13.2 mmol/L)
(Figure 1). In both groups that were examined, we also
observed a significant difference between males and females.
In female control patients, plasma NO2–/NO3– concentrations
were 74.8"16.1 mmol/L, which were significantly higher
(p-0.05) than in male controls (67.6"10.8 mmol/L), but
lower (p-0.05) than in female patients (118.2"44.7 mmol/L).
These values were significantly increased compared to male
patients (94.7"25.3 mmol/L, p-0.001) (Figure 1).
In addition, we observed that there was no significant
difference in plasma NO2–/NO3– concentrations between
patients with PANSS positive score predominance, patients
with PANSS negative score predominance, and the patients
showing almost equally positive and negative symptoms
(Table 2). Significant correlation was found between plasma
NO2–/NO3– concentrations and patient clinical characteristics
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Figure 1 Plasma NO2–/NO3– concentrations in patients with
schizophrenia.
ap-0.001 vs. control; *p-0.05 vs. control male. **p-0.05 vs. con-
trol female; ***p-0.001 vs. schizophrenia male; ****p-0.001 vs.
control male.
Table 2 Plasma nitric oxide concentrations in schizophrenic
patients with different PANSS scores.
Group n NO2–/NO3–,
mmol/L
PANSS positive 20 97.3"36.4
score predominance
PANSS negative 8 108.1"25.4
score predominance
PANSS positive and 12 100.9"26.4
negative equally expressed
The results are presented as means"SD. There was no significant
difference between tested groups.
Figure 2 Plasma NO2–/NO3– concentrations in smokers and non-
smokers.
*p-0.001 vs. control.
Table 3 Correlation between NO2–/NO3– concentrations and clinical characteristics of patients.
PBMC Heredity Number of Patient age Duration of
caspase-3 episodes at the disease psychiatric
activity onset disease
NO2–/NO3–, mmol/L rs0.264 rs0.369 rs0.408 rs0.018 rs0.037
p-0.05 p-0.01 p-0.01 p)0.05 p)0.05
including heredity (p-0.01), number of episodes (p-0.01)
and PBMC caspase-3 activity (p-0.05) (Table 3).
PBMC caspase-3 activity was significantly (p-0.05)
higher in patients compared with controls. No significant dif-
ference was found in NO2–/NO3– concentrations or in PBMC
caspase-3 activity between patient smokers (104.6"32.3
mmol/L and 0.110"0.064 mmoL/mg protein, respectively)
and non-smokers (105.1"39.5 mmol/L and 0.123"0.046
mmol/mg protein, respectively), as well as in control smokers
(70.5"17.9 mmol/L and 0.086"0.035 mmol/mg protein,
respectively) and non-smokers (68.4"12.6 mmol/L and
0.086"0.025 mmol/mg protein, respectively) (Figures 2 and
3).
Comparing plasma NO2–/NO3– concentrations between
patients treated with haloperidol (97.2"31.2 mmol/L) and
those in patients treated with atypical antipsychotic drugs
(109.8"33.7 mmol/L) revealed no significant difference
(p)0.05), although both groups had significantly higher
values compared with controls (ps0.00027) (Figure 4).
Discussion
We observed significantly higher NO2–/NO3– concentrations
in females than in males in both groups studied – healthy
subjects and schizophrenics. Similarly, Peinado et al. (11)
found that NO concentrations undergo age and gender
changes that strongly correlated with serological markers,
such as those related with cardiovascular function and lipids.
Contrary to our findings, Ghasemi et al. (12) observed sig-
nificantly higher NO metabolite concentrations in asympto-
matic male non-smokers than in females, showing peak
concentrations at the age of 50–59 years in both genders. A
study conducted in monozygotic twin pairs following an
overnight fast showed higher hereditability for females than
for males, and higher values for non-smokers than smokers,
but a low degree of heredity for NO (13). Cigarette smoking
induced an increase in serum NO concentrations associated
with increased aortic endothelial regeneration in an animal
model (14). Significant correlation between serum NO and
estradiol was observed in estrogenized males over 50 years
of age (15). This finding could explain the results of this
study considering that our studied groups consisted of sex-
ually mature and active subjects. A discrepancy in serum NO
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Figure 3 PBMC caspase-3 activity in smokers and non-smokers.
*p-0.05 vs. control.
Figure 4 Plasma NO2–/NO3– concentrations in patients with
schizophrenia treated with typical and atypical antipsychotic drugs.
*p-0.001 vs. control.
concentrations dependent on age and gender was published
elsewhere (16).
To avoid circadian variations in blood concentrations of
NO (17), as well as any influence from hyperlipidemia, we
obtained blood samples in the morning following a 12-h
fast. There was evidence that hypercholesterolemia itself sig-
nificantly lowered NO concentrations. Although patients and
controls in this study showed mean values of total cholesterol
above the upper reference interval, there was no significant
difference between males and females, or between patients
and controls. Also, the urinary excretion rate of NO2y/NO3y
was found to be decreased in uncomplicated male hyperten-
sive patients, and unrelated to accompanying insulin resis-
tence or dyslipidemia (18).
With respect to schizophrenia, it was shown that NOS
activity is significantly higher in platelets of drug naı¨ve
schizophrenic subjects compared to controls, drug-treated
schizophrenics and subjects with panic disorders (19). In
addition, it has been documented that the total amount of
NOS-immunoreactive paraventricular neurons in post mor-
tem hypotalami were smaller in depressed and schizophrenic
patients compared with normals (20). This might be related
to the presumed regulatory function of NO in the release of
corticotropin-releasing hormone and arginine-vasopressin
and/or oxytocin, which had been reported to be over-
expressed in endogenous psychoses. An increase in NOS
activity and protein in the hippocampus and cerebelum was
found in rats that were subjected to prenatal stress, and this
was correlated with behavioral changes in adults (1). Plasma
nitrate concentrations were found to be significantly
decreased, while asymmetric dimethylarginine (ADMA) was
increased in drug naı¨ve schizophrenic patients compared to
control subjects. In only three of these patients, treatment
with neuroleptics for 3 months lowered ADMA concentra-
tions and increased nitrate in plasma (21). Contrary to these
findings, a systematic review by Bernstein et al. (22) sug-
gested that alterations in NO metabolism are not unique to,
or indicative of, schizophrenia. Our results showed a highly
significant increase in plasma concentrations in– –NO /NO2 3
patients with schizophrenia compared with controls. Yilmaz
et al. (23) also found significantly higher NO in males with
chronic schizophrenia (p-0.03) compared with male con-
trols. However, Lee and Kim (24) showed significantly lower
NO concentrations in schizophrenics both before and after
treatment compared with controls. Similarly, Suzuki et al.
(25) noted no difference in plasma nitrite concentrations, but
found significantly lower plasma nitrate in schizophrenic
patients with deficit syndrome. Also, in our study there was
no significant difference in plasma NO2–/NO3– concentra-
tions between patients treated with typical or atypical anti-
psychotic drugs, or between smokers and non-smokers. With
respect to smoking status, we also measured NO2–/NO3– in
patients with ischemic heart disease and found no significant
difference between smokers and non-smokers, although
smokers in this study were much older than smokers with
schizophrenia and had a longer smoking status (6). Increases
in NO2–/NO3– concentrations in our patients may be partially
explained by the ability of atypical antipsychotic drugs to
up-regulate the expression of copper/zinc superoxide dis-
mutase mRNA and down-regulate p75NTR mRNA (26, 27),
as well as the ability of haloperidol to strongly increase the
expression of copper/zinc superoxide dismutase mRNA (27).
This enzyme is a known regulator of NO concentrations
because it scavenges superoxide anion radical and prevents
formation of toxic peroxynitrite with NO, thereby increasing
bioavalability of NO. That could be a potential cause of
increased NO2–/NO3– concentrations observed in our
patients.
The second source of NO noted in our patients might be
NOS1. NOS1 is highly expressed in the brain as well as in
the airways, intestine, kidney and heart. Recently, Kremeyer
et al. (28) found a significant association between eight sin-
gle nucleotide polymorphisms (SNPs) in the NOS1AP gene
region and schizophrenia. Others (29) have shown that some
SNPs in schizophrenics were characterized by increased gene
expression leading to higher NO production. The finding that
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the exon 1c promoter polymorphism is linked to schizophre-
nia indicates that regulatory rather than coding variants con-
vey a genetic risk for psychosis (30). These results show that
NOS1 may be responsible for the uncontrolled NO produc-
tion in patients with schizophrenia.
To date, a number of neuronal cell culture models that
were treated with different apoptotic agents such as protein
S100B, cytokines, 3,4-methyl-enedioxy-methamphetamine
or NO donors, show that the cells undergo apoptosis with
the formation of NO (31). NO can release cytochrome C
from mitochondria (32) and the apoptotic mechanism includes
caspase-3 activation following down-regulation of Bcl-2
and up-regulation of Bax protein levels (33). The evidence
for progressive clinical deterioration and subtle neuro-
structural changes following the onset of schizophrenic psy-
chosis has led to the hypothesis that apoptosis may contribute
to the pathophysiology of schizophrenia (34). Obvious mor-
phological brain changes in schizophrenics, reduced cortical
Bcl-2 protein (35), a 50% higher Bax/Bcl-2 ratio in the tem-
poral cortex of schizophrenics compared with non-psychi-
atric subjects suggest that cortical cells are vulnerable to
apoptosis (36). In favor of these postmortem findings is our
in vivo finding of increased PBMC caspase-3 activity in
patients with schizophrenia. Further studies are needed to
clarify the mechanisms underlying the increase in plasma NO
and caspase-3 activity in patients with schizophrenia.
In conclusion, the results of this study show that plasma
NO2–/NO3– concentrations are significantly increased in
patients with schizophrenia, being significantly higher in
female than male patients and healthy controls. The absence
of any correlation between patient NO2–/NO3– concentra-
tions and drug treatment and the existence of a significant
correlation between NO2–/NO3– concentrations and heredity,
number of episodes, as well as PBMC caspase-3 activity sug-
gests that NO could be considered an inducer or regulator
of apoptosis in patients with schizophrenia.
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